CellGenix Completes First Step of Facility Expansion for Cell-Culture Reagents

The company has completed the first phase of expansion at its headquarters in Freiburg, Germany, in anticipation of increasing demand as cell and gene therapies approach commercialization.
Jun 22, 2018
By BioPharm International Editors

CellGenix, a manufacturer of GMP-grade raw materials for cell therapy, gene therapy, and tissue-engineered products, has completed the first phase of its headquarters’ expansion, the company announced on June 21, 2018. The expansion is in response to customer demand, which is expected to increase as product pipelines approach late-stage clinical development and commercialization.

In a first step, the company added additional space to its headquarters in Freiburg, Germany. Quality control, research and development laboratories, logistics, and warehouse space have become operational.

In the next step, a state-of-the-art, automated filling and freeze-drying line will be implemented in the existing GMP facility, which will increase finished-product capacity for recombinant proteins by more than tenfold. This second phase of expansion is expected to be completed in the spring of 2019.

The building extension allows CellGenix to continue meeting the increasing demands for GMP-grade raw materials as new cell and gene therapies approach market authorization and commercialization.

“We are really excited about our new facility and the additional flexibility it provides. It supports our goal to become a key provider in the fight against disease, the preferred supplier of raw materials and tools, and trusted partner for large-scale manufacturing in the cell, gene therapy, and regenerative medicine space. The expansion of our facility is a result of the robust, sustainable, and profitable growth we achieved over the last years,” said Prof. Dr. Felicia Rosenthal, CEO of CellGenix, in a company press release.

“With this expansion we strengthen our position as a leading partner for all companies active in the manufacturing of cell and gene therapies. It enables us to meet increasing demands for high quality raw materials and, ultimately, help more patients,” said Frank Hecht, vice president marketing and sales, at CellGenix, in the press release.

Source: CellGenix

native1_300x100
lorem ipsum